CL2015001168A1 - Compuestos derivados de 5-amino-1h-pirazol-4-carboxamida sustituidos, inhibidores de la tirosina-quinasa de bruton (bkt); composicion farmaceutica; metodo para inhibir la bkt; y metodo para tratar enfermedades autoinmunes, inflamatorias y cancer seleccionado de un trastorno proliferativo de celula b seleccionado de linfomas. - Google Patents

Compuestos derivados de 5-amino-1h-pirazol-4-carboxamida sustituidos, inhibidores de la tirosina-quinasa de bruton (bkt); composicion farmaceutica; metodo para inhibir la bkt; y metodo para tratar enfermedades autoinmunes, inflamatorias y cancer seleccionado de un trastorno proliferativo de celula b seleccionado de linfomas.

Info

Publication number
CL2015001168A1
CL2015001168A1 CL2015001168A CL2015001168A CL2015001168A1 CL 2015001168 A1 CL2015001168 A1 CL 2015001168A1 CL 2015001168 A CL2015001168 A CL 2015001168A CL 2015001168 A CL2015001168 A CL 2015001168A CL 2015001168 A1 CL2015001168 A1 CL 2015001168A1
Authority
CL
Chile
Prior art keywords
bkt
lymphomas
pyrazol
carboxamide
inflammatory
Prior art date
Application number
CL2015001168A
Other languages
English (en)
Spanish (es)
Inventor
John Robert Springer
Balekudru Devadas
Danny James Garland
Margaret Lanahan Grapperhaus
Seungil Han
Shaun Raj Selness
Daniel Patrick Walker
Zhao-Kui Wan
Li Xing
Susan Landis Hockerman
Robert Owen Hughes
Eddine Saiah
Mark Edward Schnute
Christoph Wolfgang Zapf
Michelle Ann Schmidt
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49596360&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015001168(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of CL2015001168A1 publication Critical patent/CL2015001168A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2015001168A 2012-11-02 2015-05-04 Compuestos derivados de 5-amino-1h-pirazol-4-carboxamida sustituidos, inhibidores de la tirosina-quinasa de bruton (bkt); composicion farmaceutica; metodo para inhibir la bkt; y metodo para tratar enfermedades autoinmunes, inflamatorias y cancer seleccionado de un trastorno proliferativo de celula b seleccionado de linfomas. CL2015001168A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261721920P 2012-11-02 2012-11-02
US201361772028P 2013-03-04 2013-03-04

Publications (1)

Publication Number Publication Date
CL2015001168A1 true CL2015001168A1 (es) 2015-07-10

Family

ID=49596360

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001168A CL2015001168A1 (es) 2012-11-02 2015-05-04 Compuestos derivados de 5-amino-1h-pirazol-4-carboxamida sustituidos, inhibidores de la tirosina-quinasa de bruton (bkt); composicion farmaceutica; metodo para inhibir la bkt; y metodo para tratar enfermedades autoinmunes, inflamatorias y cancer seleccionado de un trastorno proliferativo de celula b seleccionado de linfomas.

Country Status (27)

Country Link
US (4) US20150291554A1 (enExample)
EP (1) EP2914586B1 (enExample)
JP (1) JP6178861B2 (enExample)
KR (1) KR101668574B1 (enExample)
CN (1) CN105008344B (enExample)
AP (1) AP2015008381A0 (enExample)
AU (1) AU2013340345B2 (enExample)
BR (1) BR112015009624A2 (enExample)
CA (1) CA2888960C (enExample)
CL (1) CL2015001168A1 (enExample)
CO (1) CO7350624A2 (enExample)
CR (1) CR20150228A (enExample)
DO (1) DOP2015000100A (enExample)
EA (1) EA201500393A1 (enExample)
ES (1) ES2625944T3 (enExample)
GE (1) GEP201606597B (enExample)
HK (1) HK1211293A1 (enExample)
IL (1) IL238571A0 (enExample)
MD (1) MD20150035A2 (enExample)
MX (1) MX2015005422A (enExample)
NI (1) NI201500059A (enExample)
PE (1) PE20151070A1 (enExample)
PH (1) PH12015500940A1 (enExample)
SG (1) SG11201502893WA (enExample)
TN (1) TN2015000168A1 (enExample)
TW (1) TWI518080B (enExample)
WO (1) WO2014068527A1 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201500499TA (en) 2012-08-10 2015-03-30 Boehringer Ingelheim Int Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
SI2892900T1 (en) 2012-09-10 2018-01-31 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
CN103848810A (zh) 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
JP6403751B2 (ja) 2013-03-14 2018-10-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ５−チアゾールカルボキサミン誘導体及びｂｔｋ阻害剤としてのその使用
JP6495886B2 (ja) 2013-03-15 2019-04-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害剤としての複素環式芳香族化合物
US9156847B2 (en) * 2013-03-15 2015-10-13 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
CA2901510C (en) * 2013-03-15 2022-11-29 Janssen Pharmaceutica Nv Processes for preparing ibrutinib derivatives and intermediates thereof
CN113413393B (zh) * 2013-08-19 2025-03-04 塔里斯生物医药公司 多单元药物递送装置和方法
KR102272792B1 (ko) 2013-09-30 2021-07-05 광저우 이노케어 파마 테크 씨오., 엘티디. Ｂｔｋ의 치환된 니코틴이미드 저해제 및 그의 제조 방법 및 암, 염증 및 자가면역 질환에의 용도
JP6486954B2 (ja) * 2014-01-29 2019-03-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害剤としてのピラゾール化合物
CN112353806A (zh) 2014-02-21 2021-02-12 普林斯匹亚生物制药公司 Btk抑制剂的盐和固体形式
WO2015185998A2 (en) * 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
CN105085474B (zh) 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
CN106687446B (zh) * 2014-07-18 2020-04-28 百济神州(北京)生物科技有限公司 作为t790m/wt-egfr的选择性和不可逆的激酶抑制剂的5-氨基-4-氨甲酰基-吡唑化合物及其用途
WO2016019237A2 (en) * 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
CN105884747B (zh) * 2014-08-28 2021-01-05 首药控股(北京)有限公司 一种制备布鲁顿酪氨酸激酶(btk)激酶抑制剂的制备方法
SG11201704808VA (en) 2014-12-18 2017-07-28 Principia Biopharma Inc Treatment of pemphigus
WO2016192074A1 (en) * 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016210165A1 (en) 2015-06-24 2016-12-29 Principia Biopharma Inc. Tyrosine kinase inhibitors
JP7337502B2 (ja) 2015-09-16 2023-09-04 ロクソ オンコロジー， インコーポレイテッド がんの治療のためのｂｔｋ阻害剤としてのピラゾロピリミジン誘導体
SI3377484T1 (sl) * 2015-11-17 2024-02-29 Merck Patent Gmbh Postopki za zdravljenje multiple skleroze z uporabo pirimidinskih in piridinskih spojin z btk inhibitorno aktivnostjo
LT3390390T (lt) 2015-12-16 2021-11-25 Boehringer Ingelheim International Gmbh Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
CN114716381B (zh) * 2015-12-16 2025-03-11 洛克索肿瘤学股份有限公司 可用作激酶抑制剂的化合物
US10570118B2 (en) 2016-01-13 2020-02-25 Boehringer Ingelheim International Gmbh Isoquinolones as BTK inhibitors
CN107021963A (zh) 2016-01-29 2017-08-08 北京诺诚健华医药科技有限公司 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
CN108884068B (zh) 2016-03-24 2021-02-26 特殊治疗有限公司 作为dub抑制剂的1-氰基-吡咯烷衍生物
KR102404759B1 (ko) * 2016-05-16 2022-05-31 쑤저우 시노벤트 파마슈티칼즈 씨오., 엘티디. Ｂｔｋ 억제제로서의 5-아미노피라졸 카르복사미드 유도체 및 그것의 제조 방법 및 제약학적 조성물
CN115054586B (zh) 2016-06-29 2024-08-02 普林斯匹亚生物制药公司 改性的释放制剂
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) * 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
CA3045339A1 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
AU2018346597B2 (en) 2017-10-06 2023-07-13 Forma Therapeutics, Inc. Inhibiting Ubiquitin Specific Peptidase 30
WO2019091438A1 (zh) * 2017-11-10 2019-05-16 苏州信诺维医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的无定型固体分散体
US11180475B2 (en) 2017-11-10 2021-11-23 Sinomab Bioscience Limited Crystal form I of a 5-aminopyrazole carboxamide compound as BTK inhibitor
CN111225912B (zh) * 2017-11-10 2020-11-10 苏州信诺维医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺化合物及其制备方法
JP7449242B2 (ja) 2018-05-17 2024-03-13 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物
CN108530436B (zh) * 2018-05-17 2020-12-29 黄传满 一种吡唑类化合物及其制备方法和应用
JP7530889B2 (ja) 2018-10-05 2024-08-08 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ３０（ｕｓｐ３０）阻害剤として作用する縮合ピロリン
IL286373B2 (en) * 2019-03-14 2026-03-01 Calico Life Sciences Llc Protein tyrosine phosphate inhibitor compounds and uses thereof
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
KR20220011669A (ko) * 2019-05-21 2022-01-28 얀센 파마슈티카 엔.브이. Btk 억제제 제조를 위한 방법 및 중간체
US20210106584A1 (en) 2019-10-14 2021-04-15 Principia Biopharma Inc. Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
JP7142173B2 (ja) 2019-12-06 2022-09-26 ロクソ オンコロジー， インコーポレイテッド ブルトン型チロシンキナーゼ阻害剤の投薬
US11814390B2 (en) 2020-01-22 2023-11-14 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202317099A (zh) * 2020-09-10 2023-05-01 美商絡速藥業公司 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體
MX2023002953A (es) * 2020-09-11 2023-06-01 Calico Life Sciences Llc Inhibidores de proteína tirosina fosfatasa y métodos para su uso.
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
CN115611810B (zh) * 2021-07-16 2025-03-04 深圳市塔吉瑞生物医药有限公司 取代的吡唑类化合物及包含该化合物的组合物及其用途
CN116554102B (zh) * 2022-01-28 2025-10-03 深圳海博为药业有限公司 一种作为btk抑制剂的化合物及其制备方法和应用
WO2023150663A1 (en) * 2022-02-04 2023-08-10 Retune Pharma Inc. Certain chemical entities, compositions, and methods
CN120569391A (zh) * 2023-01-19 2025-08-29 北京普祺医药科技股份有限公司 一种吡唑并环类化合物、药物组合物及其用途
WO2024153237A1 (zh) * 2023-01-19 2024-07-25 北京普祺医药科技股份有限公司 一种igf-1r酪氨酸激酶抑制剂、药物组合物及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
EP1436265A4 (en) * 2001-09-27 2004-12-15 Smithkline Beecham Corp CHEMICALS
CA2648923A1 (en) 2006-04-11 2007-10-18 Vertex Pharmaceuticals Incorporated Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
DK2526933T3 (en) * 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
FR2908409B1 (fr) 2006-11-10 2009-01-09 Sanofi Aventis Sa Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation
EP2173728A2 (en) * 2007-07-17 2010-04-14 Amgen Inc. Heterocyclic modulators of pkb
CA2730930C (en) * 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
PT2324008E (pt) 2008-07-24 2012-06-25 Nerviano Medical Sciences Srl 3,4-diarilpirazoles como inibidores da proteína quinase
NZ598985A (en) * 2009-09-04 2013-07-26 Biogen Idec Inc Bruton's tyrosine kinase inhibitors
WO2011159857A1 (en) * 2010-06-16 2011-12-22 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
SG11201500499TA (en) * 2012-08-10 2015-03-30 Boehringer Ingelheim Int Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US10105632B2 (en) 2014-04-09 2018-10-23 Donaldson Company, Inc. Self-supporting folded sheet material, filter elements, and methods
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂

Also Published As

Publication number Publication date
JP2015535277A (ja) 2015-12-10
EP2914586B1 (en) 2017-04-05
US10266513B2 (en) 2019-04-23
IL238571A0 (en) 2015-06-30
ES2625944T3 (es) 2017-07-21
TW201431851A (zh) 2014-08-16
TWI518080B (zh) 2016-01-21
JP6178861B2 (ja) 2017-08-09
HK1211293A1 (en) 2016-05-20
PH12015500940A1 (en) 2015-06-29
CR20150228A (es) 2015-09-14
US20170283393A1 (en) 2017-10-05
CA2888960C (en) 2017-08-15
CO7350624A2 (es) 2015-08-10
EP2914586A1 (en) 2015-09-09
MX2015005422A (es) 2015-08-05
CN105008344A (zh) 2015-10-28
AP2015008381A0 (en) 2015-04-30
DOP2015000100A (es) 2015-12-31
CN105008344B (zh) 2017-07-25
KR101668574B1 (ko) 2016-10-24
CA2888960A1 (en) 2014-05-08
PE20151070A1 (es) 2015-08-01
WO2014068527A1 (en) 2014-05-08
US20190202798A1 (en) 2019-07-04
MD20150035A2 (ro) 2015-10-31
SG11201502893WA (en) 2015-05-28
AU2013340345A1 (en) 2015-04-30
EA201500393A1 (ru) 2016-05-31
GEP201606597B (en) 2017-01-10
NI201500059A (es) 2015-06-05
TN2015000168A1 (fr) 2016-10-03
US20210002251A1 (en) 2021-01-07
US20150291554A1 (en) 2015-10-15
US10815213B2 (en) 2020-10-27
BR112015009624A2 (pt) 2017-11-14
KR20150075114A (ko) 2015-07-02
AU2013340345B2 (en) 2016-10-27

Similar Documents

Publication Publication Date Title
CL2015001168A1 (es) Compuestos derivados de 5-amino-1h-pirazol-4-carboxamida sustituidos, inhibidores de la tirosina-quinasa de bruton (bkt); composicion farmaceutica; metodo para inhibir la bkt; y metodo para tratar enfermedades autoinmunes, inflamatorias y cancer seleccionado de un trastorno proliferativo de celula b seleccionado de linfomas.
CL2015000094A1 (es) Compuestos derivados de imidazotriazincarbonitrilos, inhibidores de la proteina cinasa; composicion farmaceutica que los comprende; y su uso para tratar el cancer, psoriasis y artritis reumatoide.
BR112015002709A2 (pt) novos compostos de pirrolopirimidina como inibidores de proteínas quinases
CL2014003566A1 (es) Compuestos derivados de 7h-pirrolo[2,3-d]pirimidinas 4-(amimo-sustituidas), inhibidores de lrrk2; composicion farmaceutica que los comprende; y metodo para tratar la enfermedad de parkinson.
EP2721033A4 (en) COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS IDH1 MUTANT INHIBITORS FOR THE TREATMENT OF CANCER
CL2014003130A1 (es) Compuestos derivados de n-piridinil amidas ciclicas,inhibidores de quinasas pim; composicion farmaceutica que los comprende; combinacion farmaceutica; metodo para tratar enfermedades tales como canceres o un trastorno autoinmune.
SI3181567T1 (sl) Spojine pirazolopirimidina, kot inhibitorji kinaze
UY35249A (es) Inhibidores del receptor del factor de crecimiento de fibroblastos
EP2731612A4 (en) BRUTON TYROSINE KINASE HEMMER
CL2014002084A1 (es) Compuestos derivados microcíclicos, inhibidores de la quinasa del linfoma anaplásico; composicion farmaceutica; y un metodo para tratar la proliferacion celular anormal en un mamifero.
DK2683384T3 (da) Fremgangsmåder til behandling af cancer under anvendelse af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion
DK3470063T3 (da) Farmaceutiske sammensætninger til behandling af cftr-medierede sygdomme
IL236495A0 (en) Heteroaromatic compounds as proton tyrosine kinase inhibitors
DK2818482T3 (da) Farmaceutisk sammensætning til behandling af cancer
EA201491579A1 (ru) Соединения оксазолидин-2-она и их применения в качестве ингибиторов pi3k
DK2824114T3 (da) Farmaceutisk sammensætning til behandling af cancer
EA201491305A1 (ru) Конденсированные трициклические соединения в качестве ингибиторов raf киназы
SG11201503842PA (en) Pyrrolopyrimidine compounds as kinase inhibitors
MY177344A (en) Compounds and their methods of use
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201391332A1 (ru) Лиганды опиоидных рецепторов и способы их применения и получения
IN2014KN02906A (enExample)
EA201491013A1 (ru) Пиразиновые ингибиторы киназы
EP2858500A4 (en) BRUTON TYROSINE KINASE HEMMER
CL2014000543A1 (es) Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer.